The interview aims to explore the significance of new clinical data for two complementary mechanisms in immune-mediated kidney diseases: Vertex’s BAFF+APRIL inhibitor povetacicept (IgAN and pMN, RUBY-3 study) and Travere’s endothelin receptor–targeting FILSPARI (FSGS, DUPLEX study). The discussion will focus on the magnitude and durability of proteinuria reduction, eGFR stabilization, remission rates, long-term kidney failure risk modeling, and how emerging thresholds such as UPCR <0.7 g/g may redefine therapeutic targets across glomerular diseases. The conversation will also address regulatory pathways, comparative disease biology, and implications for real-world treatment sequencing once both therapies potentially reach the market.